- Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study2018 | 2. lékařská fakulta
- Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification2015 | 2. lékařská fakulta
- A Multilocus Technique for Risk Evaluation of Patients with Neuroblastoma2011 | Publikace bez příslušnosti k fakultě
- Changes in MYCN expression in human neuroblastoma cell lines following cisplatin treatment may not be related to MYCN copy numbers2013 | 1. lékařská fakulta, Fakulta tělesné výchovy a sportu, 2. lékařská fakulta
- Expulsion of amplified MYCN from homogenously staining chromosomal regions in neuroblastoma cell lines after cultivation with cisplatin, doxorubicin, hydroxyurea, and vincristine2010 | 2. lékařská fakulta
- The feasibility of using liquid biopsies as a complementary assay for copy number aberration profiling in routinely collected paediatric cancer patient samples2022 | 2. lékařská fakulta
- Využití MLPA techniky k průkazu genetických změn u neuroblastomu2008 | 2. lékařská fakulta
- Chelators as Antineuroblastomas Agents2023 | 1. lékařská fakulta
- Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials2018 | 2. lékařská fakulta
- Risk stratification of high-risk metastatic neuroblastoma: A report from the HR-NBL-1/SIOPEN study2018 | 2. lékařská fakulta
- Influence of Surgical Excision on the Survival of Patients With Stage 4 High-Risk Neuroblastoma: A Report From the HR-NBL1/SIOPEN Study2020 | 2. lékařská fakulta
- Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1)2021 | 2. lékařská fakulta
- Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial2017 | 2. lékařská fakulta